AlphAIAlphAI — Financial news for AI agents
insidermonkey.comSEP 112 min read$KIDS

OrthoPediatrics (KIDS) Crosses $70M as Guidance Climbs Higher

OrthoPediatrics (KIDS) reported Q2 revenue of $70.5M, up 15% YoY, and raised 2026 guidance to $265M-$269M. Trauma and Deformity revenue grew 26%, while international sales rose 22%. Despite higher expenses, gross margin expanded to 74% and adjusted EBITDA doubled to $6.8M. Net loss remained at $7.2M, and cash reserves declined to $47.9M.

Original reporting
insidermonkey.com
Published Sep 11, 2026, 6:15 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 11, 2026, 6:17 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
OrthoPediatrics (KIDS) Crosses $70M as Guidance Climbs Higher — source image
Source · insidermonkey.com
Decision brief

The 30-second read

$KIDSNeutralHigh
01

Why it matters

The earnings beat and guidance raise could attract growth-oriented investors, but loss persistence may deter value-focused traders.

02

Market read

First earnings release of the quarter with revenue growth and guidance lift, providing fresh trading signals for KIDS.

03

What to watch

Higher interest expense and foreign exchange losses could pressure future profitability.

Relevance 8/10Novelty 8/10Timing: post-market Aug 4

Background

OrthoPediatrics (NASDAQ:KIDS) is a specialist in pediatric orthopedic devices, recently expanding its product portfolio.

Company-level read

Ticker impact

$KIDSNeutralHigh confidence
Context

OrthoPediatrics reported Q2 revenue of $70.5M and raised its 2026 revenue guidance to $265M-$269M, the first earnings release for the quarter.

Expected impact

Potential modest upside on the news, with volatility from loss persistence.

Evidence & confidence

Guidance lift and margin expansion are positive catalysts, while flat net loss and cash decline limit upside.

Market effects

Sector

Positive signal for pediatric orthopedics and medical device sector growth.

Regional

International sales growth highlights demand outside the U.S.

Global

Limited to niche medical device investors.

Counterpoint

What could challenge this read

Flat net loss and shrinking cash may outweigh revenue growth, suggesting caution.

Key entities

  • Company
    OrthoPediatrics Corp.

    Pediatric orthopedics device maker.

  • Company
    OSSIO

    Partner for exclusive distribution of metal‑free fixation technology.

Read at source← All news

Related articles

AUG 6
$KIDSMed

OrthoPediatrics Corp. Q2 2026 Earnings Call Summary

OrthoPediatrics reported Q2 2026 progress toward a “financial inflection point,” citing record adjusted EBITDA margins near 10% and a shift toward positive free cash flow. Trauma and Deformity revenue grew 26% on implant share gains and early 3P Hip deployments. Management expects positive free cash flow in H2 2026 and FCF break-even or better for full-year 2026, with conservative timing assumptions for capital placements and international orders.

yahoo.com7 min
SEP 22
$AZOMedAI 8/10

AutoZone Q4 EPS Hits $56.05 as Annual Sales Reach $20.3bn

AutoZone (AZO) reported Q4 2026 EPS of $56.05, up from $48.71 a year earlier, with net sales of $6.6bn, a 5.6% increase. Full-year sales reached $20.3bn, up 7.4%. Gross margin rose to 53.3%, boosted by tariff refunds and LIFO benefits. The company opened 175 new stores, ending the year with 8,031 locations. Shares rose 4.33% post-earnings.

financial-news.co.uk2 min
SEP 22
$AZOHighAI 8/10

Why AutoZone (AZO) Stock Is Trading Up Today

AutoZone (AZO) shares rose 6.1% after reporting Q4 EPS of $56.05, beating estimates. Net sales were $6.6B, missing expectations. Same-store sales grew 1.6%, and gross margin expanded 182 bps to 53.3%. The company's stock has had limited volatility, with today's move being notable. AZO is down 9.9% YTD, trading 30.6% below its 52-week high.

financialcontent.com2 min
SEP 22
$MLKNHighAI 8/10

MillerKnoll, Inc. Q1 2027 Earnings Call Summary

MillerKnoll reported a 3.4% revenue decline in Q1 2027 due to soft North American demand, offset by international growth. The company lowered full-year sales guidance to $3.88B-$4.03B but maintained EPS outlook. Management cited tariffs, inflation, and election uncertainty as challenges, while focusing on cost management and debt reduction. Orders improved in September, showing growth across all segments.

yahoo.com3 min